Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Safety of New and Old Formulations of HRS-2189 Tablets in Healthy Subjects
NCT07639905Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hrs-2189 in malignant solid tumor (2 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum plasma concentration, Area under the blood drug concentration-time curve from time 0 to the last quantifiable concentration and 1 more. Started Jun 2026; status: completed.
02
Drugs
hrs-2189
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07639905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639905.